Photo: Rendering of a human brain. Shawn Day / Unsplash
1. Synchron pauses trials of Stentrode brain implant over lead performance issue
The company says the problem is in the cable, not the stent-mounted electrode array itself.
Synchron has paused enrollment in clinical trials of its second-generation Stentrode brain-computer interface after the device failed to perform as expected in initial participants, Becker's reported Nov. 13, citing WIRED [1]. The company traced the problem to the lead that carries signals from the Stentrode to the implanted electronics, said no device safety issues have been identified, and described the pause as a company decision rather than an FDA-directed action [1]. Synchron has brought lead design and manufacturing in-house, plans to upgrade the entire system before resuming enrollment, and is restructuring with job cuts in New York and a new team in San Diego [1].
2. FDA issues complete response letter for Summit's ivonescimab in EGFR-mutated lung cancer
A progression-free survival win was not enough without a significant overall survival benefit.
Summit Therapeutics said Nov. 15 that the FDA declined to approve its BLA for ivonescimab plus platinum chemotherapy in locally advanced or metastatic non-small cell lung cancer after EGFR TKI therapy, stating the application "cannot be approved in its present form" [2]. The global Phase 3 HARMONi trial met its PFS endpoint, but overall survival showed only a positive trend at the primary analysis, and the FDA said PFS benefit without a statistically significant OS improvement does not establish a positive benefit-risk profile [2]. Summit said it will continue developing the drug in ongoing Phase 3 trials including HARMONi-3 and HARMONi-7 [2].
3. CDC: early flu season under way, seven jurisdictions at high activity, H1N1 predominant
Outpatient influenza-like illness has crossed the national baseline.
For the week ending Nov. 7, 3.2% of outpatient visits were for influenza-like illness, above the 2.9% national baseline, with one jurisdiction at very high and six at high activity [3]. Influenza A(H1N1)pdm09 accounted for 455 of 460 subtyped influenza A viruses, and the CDC estimates at least 2.6 million illnesses, 36,000 hospitalizations and 2,100 deaths so far this season [3]. Two pediatric deaths were reported this week, bringing the 2026-27 season total to five [3].
4. Medline bed recall now linked to seven deaths and 35 serious injuries
The company has launched a repair-and-replace program for beds sold since 2011.
An FDA notice posted Nov. 13 says Medline has received reports of seven deaths and 35 serious injuries as of Nov. 8 connected to its recall of all Medline Brand beds, rails, mattresses and accessories, which the company initiated on Oct. 14 along with its exit from the bed market [4]. The hazards are a potential fire risk and entrapment risk; the products were distributed in the U.S. and Canada from 2011 to 2026 [4]. Some beds may be eligible for authorized repair, and those that cannot be repaired may qualify for replacement or a full or partial refund; in the meantime, users are told to keep beds unplugged except while repositioning a patient [4].
Digest references
Becker's Hospital Review, "Synchron pauses enrollment in brain implant trials over performance issue," Nov. 13, 2026. beckershospitalreview.com
Summit Therapeutics (Business Wire), "Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application," Nov. 15, 2026. financialcontent.com
Centers for Disease Control and Prevention, "Weekly U.S. Influenza Surveillance Report: Week 44, ending November 7, 2026." cdc.gov
U.S. Food and Drug Administration, "Medline Updates Customers and Patients on Repair and Replace Program for Recall of Medline Brand Beds, Rails, Mattresses and Accessories," Nov. 13, 2026. fda.gov